MapLight Therapeutics, Inc. Common Stock MPLT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T16:16:33.387Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:35:17.491197706Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T16:16:32.393478+00:00
MapLight Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.81 | 603.5% | 56.0% | |||
| 25Δ | 5.68 | 529.1% | 46.9% | |||
| 30Δ | 23.92 | 566.6% | 227.6% | 6.55 | 454.7% | 37.8% |
| 35Δ | 14.70 | 422.8% | 106.3% | 7.42 | 380.3% | 28.8% |
| 40Δ | 11.91 | 371.1% | 71.0% | 8.74 | 388.5% | 25.7% |
| 45Δ | 10.96 | 361.6% | 60.8% | 10.11 | 404.8% | 23.3% |
| 50Δ | 10.01 | 352.2% | 50.5% | 11.47 | 421.0% | 20.8% |
| 55Δ | 9.05 | 342.7% | 40.3% | 12.84 | 437.3% | 18.4% |
| 60Δ | 8.10 | 333.2% | 30.1% | |||
| 65Δ | 19.49 | 546.7% | 15.3% | |||
| 70Δ | 36.67 | 696.6% | 14.5% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.81
- IV
- 603.5%
- B/E move
- 56.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.68
- IV
- 529.1%
- B/E move
- 46.9%
30Δ
- Pseudo strike
- 23.92
- IV
- 566.6%
- B/E move
- 227.6%
- Pseudo strike
- 6.55
- IV
- 454.7%
- B/E move
- 37.8%
35Δ
- Pseudo strike
- 14.70
- IV
- 422.8%
- B/E move
- 106.3%
- Pseudo strike
- 7.42
- IV
- 380.3%
- B/E move
- 28.8%
40Δ
- Pseudo strike
- 11.91
- IV
- 371.1%
- B/E move
- 71.0%
- Pseudo strike
- 8.74
- IV
- 388.5%
- B/E move
- 25.7%
45Δ
- Pseudo strike
- 10.96
- IV
- 361.6%
- B/E move
- 60.8%
- Pseudo strike
- 10.11
- IV
- 404.8%
- B/E move
- 23.3%
50Δ
- Pseudo strike
- 10.01
- IV
- 352.2%
- B/E move
- 50.5%
- Pseudo strike
- 11.47
- IV
- 421.0%
- B/E move
- 20.8%
55Δ
- Pseudo strike
- 9.05
- IV
- 342.7%
- B/E move
- 40.3%
- Pseudo strike
- 12.84
- IV
- 437.3%
- B/E move
- 18.4%
60Δ
- Pseudo strike
- 8.10
- IV
- 333.2%
- B/E move
- 30.1%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.49
- IV
- 546.7%
- B/E move
- 15.3%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 36.67
- IV
- 696.6%
- B/E move
- 14.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 163.02% | |
| 97.63% | |
| 111.78% | |
| 130.05% | |
| 131.84% | |
| 96.49% | |
| 135.89% | |
| 129.84% | |
| 133.23% | |
| 137.63% | |
| 139.05% | |
| 139.85% | |
| 152.66% | |
| 147.86% | |
| 161.80% | |
| 186.64% | |
| 188.59% | |
| 126.33% | |
| 159.56% | |
| 154.38% | |
| 138.52% | |
| 150.24% | |
| 135.75% | |
| 167.81% | |
| 179.59% | |
| 162.26% | |
| 165.97% | |
| 95.36% | |
| 111.76% | |
| 121.27% | |
| 121.92% | |
| 136.36% | |
| 143.57% | |
| 213.90% | |
| 121.33% | |
| 112.57% | |
| 170.69% | |
| 199.93% | |
| 190.49% | |
| 117.62% | |
| 127.05% |
Biotechnology
MRNA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases,…
More →MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →NAMS
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its…
More →NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →NBTX
Description unavailable
More →NGNE
Description unavailable
More →